Gapping down
News:
- ENTA -5.4% (to present data for EDP-323, its Oral, once-daily, L-Protein inhibitor in development for the treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference)
- ORTX -3.3% (FDA has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of March 18, 2024)
- VFS -2.2% (Q2 deliveries)
- IONS -1.6% (treatment of Pelizaeus-Merzbacher disease granted FDA orphan designation on Friday)
- CLX -1.2% (identified unauthorized activity on some of its Information Technology systems; believes the impact will be material on Q1 financial results)
- DNA -1.2% (Ginkgo Bioworks and Factorial Biotechnologies announce a new collaboration)
- AU -1.1% (B2Gold to consolidate Gramalote Project by acquiring AngloGold Ashanti's (AU) 50% Stake)
- ACRS -1.1% (Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor)
Analyst comments:
- PAY -4% (downgraded to Neutral from Outperform at Robert Baird)
- DBX -2.6% (downgraded to Mkt Perform from Outperform at William Blair)
- NTAP -1.6% (downgraded to Mkt Perform from Outperform at William Blair)